Literature DB >> 35450527

Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial.

Arianna Di Stadio1, Luca D'Ascanio2, Luigi Angelo Vaira3,4, Elena Cantone5, Pietro De Luca6, Cristina Cingolani2, Gaetano Motta5, Giacomo De Riu3, Federica Vitelli2, Giuseppe Spriano7,8, Marco De Vincentiis9, Angelo Camaioni10, Ignazio La Mantia1, Fabio Ferreli7,8, Michael J Brenner11.   

Abstract

BACKGROUND: Olfactory training is the only evidence-based treatment for post-viral olfactory dysfunction. Smell disorders after SARS-CoV-2 infection have been attributed to neuroinflammatory events within the olfactory bulb and the central nervous system. Therefore, targeting neuroinflammation is one potential strategy for promoting recovery from post-COVID-19 chronic olfactory dysfunction. Palmitoylethanolamide and luteolin (PEA-LUT) are candidate antiinflammatory/ neuroprotective agents.
OBJECTIVE: To investigate recovery of olfactory function in patients treated with PEA-LUT oral supplements plus olfactory training versus olfactory training plus placebo.
METHODS: Multicenter double-blinded randomized placebo-controlled clinical trial was held. Eligible subjects had prior COVID-19 and persistent olfactory impairment >6 months after follow-up SARS-CoV-2 negative testing, without prior history of olfactory dysfunction or other sinonasal disorders. Participants were randomized to daily oral supplementation with ultramicronized PEA-LUT 770 mg plus olfactory training (intervention group) or olfactory training with placebo (control). Sniffin' Sticks assessments were used to test the patients at baseline and 90 days.
RESULTS: A total of 185 patients, including intervention (130) and control (55) were enrolled. The intervention group showed significantly greater improvement in olfactory threshold, discrimination, and identification scores compared to controls (p=0.0001). Overall, 92% of patients in the intervention group improved versus 42% of controls. Magnitude of recovery was significantly greater in the intervention group versus control (12.8 + 8.2 versus mean 3.2 + 3), with >10-fold higher prevalence of anosmia in control versus intervention groups at the 90-day endpoint.
CONCLUSION: Among individuals with olfactory dysfunction post-COVID-19, combining PEA-LUT with olfactory training resulted in greater recovery of smell than olfactory training alone. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; anosmia; anti-inflammatory; coronavirus; hyposmia; olfaction; olfactory dysfunction; olfactory training

Mesh:

Substances:

Year:  2022        PMID: 35450527     DOI: 10.2174/1570159X20666220420113513

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.708


  7 in total

Review 1.  Potential mechanism of SARS-CoV-2-associated central and peripheral nervous system impairment.

Authors:  Yan Zhang; Xue Chen; Lin Jia; Yulin Zhang
Journal:  Acta Neurol Scand       Date:  2022-06-14       Impact factor: 3.915

Review 2.  Classical and Unexpected Effects of Ultra-Micronized PEA in Neuromuscular Function.

Authors:  Pierangelo Cifelli; Gabriele Ruffolo; Marco Ceccanti; Chiara Cambieri; Laura Libonati; Eleonora Palma; Maurizio Inghilleri
Journal:  Biomolecules       Date:  2022-05-29

3.  Entorhinal Cortex and Persistent Olfactory Loss in COVID-19 Patients: A Neuroanatomical Hypothesis. Comment on Fiorentino et al. Correlations between Persistent Olfactory and Semantic Memory Disorders after SARS-CoV-2 Infection. Brain Sci. 2022, 12, 714.

Authors:  Pietro De Luca; Pasquale Marra; Ignazio La Mantia; Francesco Antonio Salzano; Angelo Camaioni; Arianna Di Stadio
Journal:  Brain Sci       Date:  2022-06-29

4.  The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study.

Authors:  Loredana Raciti; Rosaria De Luca; Gianfranco Raciti; Francesca Antonia Arcadi; Rocco Salvatore Calabrò
Journal:  Med Sci (Basel)       Date:  2022-07-14

5.  Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study.

Authors:  Pietro De Luca; Angelo Camaioni; Pasquale Marra; Giovanni Salzano; Giovanni Carriere; Luca Ricciardi; Resi Pucci; Nicola Montemurro; Michael J Brenner; Arianna Di Stadio
Journal:  Cells       Date:  2022-08-17       Impact factor: 7.666

6.  Persistent or new symptoms 1 year after a single high dose of vitamin D3 in patients with moderate to severe COVID-19.

Authors:  Alan L Fernandes; Lucas P Sales; Mayara D Santos; Valeria F Caparbo; Igor H Murai; Rosa M R Pereira
Journal:  Front Nutr       Date:  2022-09-13

7.  COVID-19 related persistent olfactory disorders represent an unprecedented challenge.

Authors:  Luigi Angelo Vaira; Giacomo De Riu; Giovanni Salzano; Fabio Maglitto; Paolo Boscolo-Rizzo; Jerome R Lechien
Journal:  Am J Otolaryngol       Date:  2022-10-17       Impact factor: 2.873

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.